Project Grant R01AI195050
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $696,200 Project Grant to The Johns Hopkins University, with performance in Baltimore, Maryland, to conduct the On-Demand HIV Prevention Across the Lifespan (OPAL) Study from May 12, 2026, through April 30, 2031, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The OPAL Study addresses critical knowledge gaps in biomedical HIV prevention for women by evaluating the...
- Project Summary: MISTR+ Study on Telehealth PrEP Delivery The National Institute of Allergy and Infectious Diseases (NIAID) awarded Emory University $1,273,269 on June 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct the MISTR+ study, which will operate through May 31, 2031. This project aims to establish an evidence base for telemedicine-delivered HIV pre-exposure prophylaxis (PrEP) and improve health outcomes for over 100,000 users of the largest...
- PHARMA-GIRL Project Grant Summary The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) awarded a $408,643 Project Grant (CFDA 93.865: Child Health and Human Development Extramural Research) to The Regents of the University of California, San Francisco, effective February 1, 2026, through January 31, 2028. This research initiative, titled "PHARMA-GIRL: Empowering Adolescent Girls and Young Women with Choice and Prevention in Pharmacy-Based HIV...
- The National Institute of Mental Health (NIMH) awarded a $632,775 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to the University of Georgia Research Foundation. The grant aims to develop and pilot test the EMPOWER (Enhancing and Motivating PrEP Options among Women through Empowerment and Resilience) telehealth intervention to optimize pre-exposure prophylaxis (PrEP) uptake and persistence among African American women in the southern United States. The project...
- Federal Grant Award Summary New York University School of Medicine received a $256,165 Project Grant award dated May 15, 2026, from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and evaluate PREP-RISE, a multi-level intervention designed to increase pre-exposure prophylaxis (PrEP) uptake and adherence among women who inject drugs (WWID). The intervention combines photovoice—a participatory community-based research...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $381,487 to the University of Maryland, Baltimore (UMB) to assess the early implementation of long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) among adolescent girls and young women (AGYW) at high risk of HIV acquisition in Zambia. The key objectives are to: 1) Evaluate implementation determinants of CAB-LA...
- Federal Project Grant Award Summary Award Details: Empowerx, Inc., a woman-owned small business, received a $485,654 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) on September 22, 2025, with completion targeted for August 31, 2026. Products and Services: The awardee will develop the PEP/PREP via Pharmacist-Prescribing Implementation (PEPPI) software platform to increase access to Post-Exposure Prophylaxis (PEP) and...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Johns Hopkins University a $1,995,285 Project Grant effective June 10, 2026, through June 9, 2029, under the Mental Health Research Grants program (CFDA 93.242). This research initiative will conduct a national study to assess the reach and public health impact of pharmacist-prescribed HIV pre-exposure prophylaxis (PrEP). The research will evaluate where pharmacist-prescribed PrEP is occurring or not occurring...
- Federal Project Grant Award Summary The University of Connecticut received $755,118 in federal funding under the Drug Use and Addiction Research Programs (CFDA 93.279) administered by the National Institute on Drug Abuse (NIDA) to conduct a five-year research study examining premature PrEP (Pre-Exposure Prophylaxis) discontinuation among men aged 18-35. The award, issued on May 15, 2026, with completion targeted for February 28, 2031, supports a multilevel mixed-methods longitudinal research...
- Grant Award Summary The Fogarty International Center awarded Impact Research and Development Organisation (IRDO) a $234,292 Project Grant (CFDA 93.989: International Research and Research Training) effective September 13, 2025, through August 31, 2028, to develop and pilot test a multilevel, community-based intervention addressing pre-exposure prophylaxis (PrEP) stigma among adolescent girls and young women (AGYW) ages 15–24 in western Kenya. The project deliverables include participatory...
The POWER (PrEP Optimization in Women via Event-Driven Regimens) Study is a five-year research initiative funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). Awarded to The Johns Hopkins University on July 6, 2026, with $691,288 in federal obligations and a completion date of June 30, 2031, this project addresses critical knowledge gaps in HIV pre-exposure prophylaxis (PrEP) efficacy among women on therapeutic testosterone. The research focuses on quantifying emtricitabine/tenofovir disoproxil fumarate (F/TDF) concentrations at anatomical sites of sexual exposure—specifically the female genital tract and rectum—to evaluate whether testosterone-mediated immune modulation affects PrEP pharmacokinetics, pharmacodynamics, and protective efficacy. The deliverables include pharmacological data characterizing F/TDF concentrations in the female genital tract during event-driven ("2-1-1") dosing regimens, analysis of testosterone-induced changes in cervicovaginal immunomodulatory markers, and assessment of HIV acquisition risk in women receiving exogenous hormone therapy. By closing existing evidence gaps regarding hormone-PrEP interactions and less-than-daily dosing regimens, this research will inform clinical guidance on optimal PrEP strategies for transgender and gender-diverse women and cisgender women using therapeutic testosterone, ultimately advancing HIV prevention approaches for this underserved population.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $691.3k | 7/6/26 |